Idiopathic Pulmonary Fibrosis Clinical Research Network

特发性肺纤维化临床研究网络

基本信息

批准号：
7615134
负责人：
Jay H. Ryu
金额：
$ 16.67万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-05-01 至 2013-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7615134
关键词：
Acetylcysteine Adrenal Cortex Hormones Alveolar Alveolitis Anti-Inflammatory Agents Anti-inflammatory Basic Science Cessation of life Characteristics Cicatrix Clinic Clinical Clinical Investigator Clinical Research Clinical Trials Colchicine Commit Coughing Cytotoxic agent Data Databases Development Diagnosis Disease Disease Progression Double-Blind Method Dyspnea Epithelial Fibrosis Funding Goals Hamman-Rich syndrome Imatinib Inflammation Inflammatory Injury Interferon Type II Interstitial Lung Diseases Investigation Knowledge Lung Lung diseases Mediating Morbidity - disease rate Outcome Oxidants Participant Pathogenesis Pathway interactions Patients Pattern Pentoxifylline Pharmaceutical Preparations Pharmacotherapy Placebos Platelet-Derived Growth Factor Process Publishing Randomized Registries Research Respiratory Failure Role Signal Transduction TNF gene Therapeutic Agents Therapy Clinical Trials Time Transforming Growth Factor beta Treatment Protocols Tumor Necrosis Factor-alpha Vital capacity base computerized control trial cytokine effective therapy experience improved injury and repair interest interstitial lung injury mortality novel novel therapeutics traditional therapy

项目摘要

DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease that commonly results in respiratory failure and death with a median survival of three years after diagnosis. Recent studies demonstrate traditional therapy consisting of corticosteroids and cytotoxic agents to be ineffective in improving survival. There is currently no effective treatment for this disorder. Recent advances in basic research on the pathogenesis of IPF and the development of novel therapeutic agents have increased the need for a cooperative clinical research network in evaluating new management strategies. An established group of clinical investigators (Mayo Interstitial Lung Disease Group) with a longstanding interest and track record in IPF proposes the development of a clinical center at Mayo Clinic to participate in the NIH-funded IPF Clinical Research Network for conducting collaborative therapeutic trials. These clinical investigators and their research staff of the Pulmonary Clinical Research Center have considerable experience in recruitment and retention of subjects for clinical trials in IPF and other lung diseases. This clinical center proposes two treatment studies for consideration by the network. The first study will examine the effects of combined imatinib and pentoxifylline regimen compared to placebo in the treatment of IPF. The second project will study the effects of combined colchicines and N-acetylcysteine therapy compared to placebo. To conduct these and other IPF Clinical Research Network studies, this clinical center will draw from 200-250 new patients with IPF seen each year at Mayo Clinic Rochester. The Mayo Interstitial Lung Disease Clinic registry and computerized databases will allow identification and participation of other subjects with IPF previously seen at this clinical center. This clinical center will also have access to other potential participants seen at Mayo Clinic Jacksonville (FL) and Mayo Clinic Scottsdale (AZ). (End of Abstract)

描述（由申请人提供）：特发性肺纤维化（IPF）是一种进行性肺部疾病，通常导致呼吸衰竭和死亡，中位生存期在诊断后三年。最近的研究表明，由皮质类固醇和细胞毒性剂组成的传统疗法在改善生存方面无效。目前尚无对这种疾病的有效治疗方法。关于IPF发病机理的基础研究和新型治疗剂的发展的最新进展增加了对评估新管理策略的合作临床研究网络的需求。 IPF中长期兴趣和记录的一组既定的临床研究者（Mayo间质肺病组）提出，在Mayo Clinic的临床中心开发，以参与NIH资助的IPF临床研究网络，以进行协作治疗试验。这些临床研究人员及其肺临床研究中心的研究人员在招募和保留IPF和其他肺部疾病临床试验的受试者方面具有丰富的经验。该临床中心提出了两项治疗研究，以供网络考虑。第一项研究将研究与安慰剂在IPF治疗中相比，伊马替尼和戊替林素治疗方案的效果。与安慰剂相比，第二个项目将研究秋水仙碱和N-乙酰半胱氨酸疗法的影响。为了进行这些IPF临床研究网络研究，该临床中心将从每年在Mayo Clinic Rochester上观看200-250名新IPF患者。蛋黄酱的间质性肺疾病诊所注册表和计算机数据库将允许以前在该临床中心看到的IPF识别和参与其他受试者。该临床中心还将可以与Mayo Clinic Jacksonville（FL）和Mayo Clinic Scottsdale（AZ）见到其他潜在参与者。（抽象的结尾）

项目成果

期刊论文数量（11）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.

DOI：
10.1016/j.rmed.2012.06.018
发表时间：
2012-10
期刊：
RESPIRATORY MEDICINE
影响因子：
4.3
作者：
Swigris, Jeffrey J.;Han, Meilan;Vij, Rekha;Noth, Imre;Eisenstein, Eric L.;Anstrom, Kevin J.;Brown, Kevin K.;Fairclough, Diane
通讯作者：
Fairclough, Diane

Advances in the management of idiopathic pulmonary fibrosis.

DOI：
10.3410/m2-28
发表时间：
2010-04-12
期刊：
F1000 medicine reports
影响因子：
0
作者：
Ryu JH;Daniels CE
通讯作者：
Daniels CE

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.

DOI：
10.1056/nejmoa1401739
发表时间：
2014-05-29
期刊：
The New England journal of medicine
影响因子：
0
作者：
Idiopathic Pulmonary Fibrosis Clinical Research Network;Martinez FJ;de Andrade JA;Anstrom KJ;King TE Jr;Raghu G
通讯作者：
Raghu G

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

DOI：
10.1056/nejmoa1113354
发表时间：
2012-05-24
期刊：
The New England journal of medicine
影响因子：
0
作者：
Idiopathic Pulmonary Fibrosis Clinical Research Network;Raghu G;Anstrom KJ;King TE Jr;Lasky JA;Martinez FJ
通讯作者：
Martinez FJ